Biocon Ltd Share Price
(BIOCON)
₹341.7
as on 04:01PM, 28 Mar 2025
Biocon Performance
Day's Low
Day's High
₹339.35Day's Price Range₹349.352 Week's Low
52 Week's High
₹25152-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | + 14.25 % |
| 3 Month Return | -6.02 % |
| 1 Year Return | + 30.82 % |
| Market Stats | |
| Previous Close | ₹345.55 |
| Open | ₹344.95 |
| Volume | 23.40L |
| Upper Circuit | ₹380.10 |
| Lower Circuit | ₹311.00 |
| Market Cap | ₹41,486.73Cr |
Biocon Fundamentals
P/E Ratio
51.42
PEG Ratio
-15.49
Market Cap
₹41,486.73 Cr
P/B Ratio
2.91
EPS
10.81
Dividend Yield
0.19
Sector
Pharmaceuticals
ROE
0.97
Mutual Fund Holdings of Biocon
Biocon Analyst Rating
based on 20 analysts
57.89%
Buy
15.79%
Hold
26.32%
Sell
Based on 20 analysts offering long term price targets for Biocon. An average target of ₹381.45
Source: S&P Global Market Intelligence
Biocon Share analysis
Biocon price forecast by 20 analysts
Upside of10.39%
High
₹452
Target
₹381.45
Low
₹260
Biocon target price ₹381.45, a slight upside of 10.39% compared to current price of ₹341.7. According to 20 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:40.00%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:47.89%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Biocon Ltd
Biocon Biologics Secures Major UK Joint Venture Guarantees - 26 Mar, 2025
In October, Biocon Biologics issued guarantees for its UK joint venture, Biocon Biologics UK Ltd, representing one of the largest remittances to the UK in FY25.Biocon Secures FDA Approval for Key Injectable Drug - 24 Mar, 2025
Biocon's subsidiary, Biocon Pharma, has received US FDA approval for Norepinephrine Bitartrate Injection, a critical drug for treating acute hypotension, boosting its complex drug portfolio.Biocon Reports Positive Trial Results and Collaboration - 07 Mar, 2025
Biocon Biologics announced a strategic collaboration with Civica, Inc. to improve Insulin Aspart access in the U.S. Additionally, positive phase 3 results for Yesintek, a psoriasis biosimilar, were reported, confirming its efficacy and safety compared to Stelara.Biocon Collaborates with Civica for Insulin Aspart Supply - 06 Mar, 2025
Biocon Biologics has entered a partnership with Civica, Inc. to supply Insulin Aspart drug substance, aiming to improve access and affordability for diabetes patients in the US. Civica will commercialize the product after development and clinical trials, with no technology transfer involved.Biocon Gains FDA Approvals, Shares Rise 3% - 05 Mar, 2025
Biocon Pharma secured final FDA approvals for Lenalidomide and Dasatinib, alongside tentative approval for Rivaroxaban. Following this, Biocon shares increased by 3%, reflecting positive market sentiment.Biocon Achieves FDA Approvals and Market Growth - 04 Mar, 2025
Biocon's subsidiary secures FDA approvals for Lenalidomide and Dasatinib. The company targets mid-teen revenue growth, with a notable increase in Insulin Glargine market share.Biocon Launches Liraglutide Amid Stock Decline - 28 Feb, 2025
Biocon launched its GLP-1 drug Liraglutide in the UK, becoming the first generics company to gain approval. However, shares fell 3.92%, indicating investor concerns.Biocon Shares Rise After YESINTEK Launch in U.S. - 25 Feb, 2025
Biocon's stock surged over 2% following the U.S. launch of YESINTEK™, a cost-effective biosimilar to Stelara® for treating chronic autoimmune diseases. The launch includes commercial payor coverage and a patient assistance program.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 7.97% to 8.58% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, BIOCON stock has moved up by 14.3%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 3.64K Cr → 3.87K Cr (in ₹), with an average increase of 5.8% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -16.0 Cr → 25.1 Cr (in ₹), with an average increase of 163.8% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Vimta Labs Ltd has given 214.0% return, outperforming this stock by 214.0%
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 127.4% return, outperforming this stock by 96.6%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 5.93% to 5.66% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 18.75% to 18.12% in Dec 2024 quarter
Biocon Financials
Biocon Index Inclusions
Biocon Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.66% | ||
| Mutual Funds | 8.58% | 7.71 | |
| Retail Investors | 18.12% | ||
| Others | 7% | 4.30 |
Biocon Key Indicators
Biocon Valuation
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (51.42x)
March 27, 2025
Industry (53.19x)
March 27, 2025
Highest (118.86x)
September 27, 2018
Biocon Earnings and Dividends
Biocon Ltd Earnings Results
Biocon Ltd’s net profit fell -96.2% since last year same period to ₹25.10Cr in the Q3 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 256.88% jump in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.59%.
Read More about Dividends
Biocon Technicals Summary
Bearish
Neutral
Bullish
Biocon Ltd is currently in a Bearish trading position according to technical analysis indicators.
Biocon Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹41,486.73 Cr | 5.08% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹1,55,900.41 Cr | 42.02% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,419.57 Cr | 45.98% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹26,440.93 Cr | -2.36% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,19,761.54 Cr | 48.69% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Revenue: ₹3,773.00Cr as on December 2024 (Q4 24)
Net Profit: ₹81.10Cr as on December 2024 (Q4 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Biocon Ltd
What is Biocon Ltd price today?
Biocon Ltd share price today stands at ₹341.7, Open: ₹344.95, Previous Close: ₹345.55, High: ₹349.3, Low: ₹339.35, 52 Week High: ₹404.7, 52 Week Low: ₹251.
How to Buy Biocon Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Biocon Ltd shares
What are today's traded volumes of Biocon Ltd?
Today's traded volume of Biocon Ltd(BIOCON) is 23.40L.
What is today's market capitalisation of Biocon Ltd?
Today's market capitalisation of Biocon Ltd(BIOCON) is ₹41486.73Cr.
What is the 52 Week High and Low Range of Biocon Ltd?
How much percentage Biocon Ltd is down from its 52 Week High?
Biocon Ltd (BIOCON) share price is ₹341.7. It is down -15.57% from its 52 Week High price of ₹404.7
How much percentage Biocon Ltd is up from its 52 Week low?
Biocon Ltd (BIOCON) share price is ₹341.7. It is up 36.14% from its 52 Week Low price of ₹251